Compare · ENVB vs NVS
ENVB vs NVS
Side-by-side comparison of Enveric Biosciences Inc. (ENVB) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENVB and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $284.62B, about 42946.0x ENVB ($6.6M).
- Over the past year, ENVB is down 88.8% and NVS is up 24.1% - NVS leads by 112.9 points.
- ENVB has hit the wire 12 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 3 for ENVB).
- Company
- Enveric Biosciences Inc.
- Novartis AG
- Price
- $1.75-1.13%
- $146.50-1.72%
- Market cap
- $6.6M
- $284.62B
- 1M return
- -43.91%
- +0.71%
- 1Y return
- -88.78%
- +24.12%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 12
- 0
- Recent ratings
- 3
- 25
Enveric Biosciences Inc.
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest ENVB
- Chief Financial Officer Coveney Kevin Michael was granted 133,333 shares, increasing direct ownership by 281% to 180,746 units (SEC Form 4)
- Chief Executive Officer Tucker Joseph Edward was granted 201,124 shares, increasing direct ownership by 286% to 271,479 units (SEC Form 4)
- Director Pasqualone Frank was granted 18,518 shares, increasing direct ownership by 234% to 26,423 units (SEC Form 4)
- Director Webb Michael D was granted 18,518 shares, increasing direct ownership by 234% to 26,416 units (SEC Form 4)
- Director Schabacker Marcus was granted 18,518 shares, increasing direct ownership by 234% to 26,418 units (SEC Form 4)
- Director Kegler George A. was granted 18,518 shares, increasing direct ownership by 234% to 26,418 units (SEC Form 4)
- Director Dewitt Sheila was granted 18,518 shares, increasing direct ownership by 238% to 26,306 units (SEC Form 4)
- Chief Innovation Officer Facchini Peter J. was granted 25,000 shares, increasing direct ownership by 907% to 27,755 units (SEC Form 4)
- Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
- SEC Form S-8 filed by Enveric Biosciences Inc.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG